Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Suhani Sinha, Sonali, Vandana Garg, Sonia Thapa, Shashank Singh, Mahima Chauhan, Rohit Dutt & Rahul Pratap Singh. (2022) Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity. Drug Development and Industrial Pharmacy 48:7, pages 279-291.
Read now
Read now
Jyotsana Pandey & Akhilesh K Tamrakar. (2019) SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). Expert Opinion on Therapeutic Patents 29:5, pages 369-384.
Read now
Read now
Anda Mihaela Naciu & Paolo Pozzilli. (2018) Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients. Expert Opinion on Pharmacotherapy 19:4, pages 355-364.
Read now
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2017) Dapagliflozin for the treatment of type 1 diabetes mellitus. Expert Opinion on Investigational Drugs 26:7, pages 873-881.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Read now
Jay H Shubrook, Babak Baradar Bokaie & Sarah E Adkins. (2015) Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy 9, pages 5793-5803.
Read now
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Kashif M Munir & Stephen N Davis. (2015) The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 16:15, pages 2331-2341.
Read now
Read now
Articles from other publishers (25)
Roxana Pérez-Villavicencio, Javier Flores-Estrada, Martha Franco, Bruno Escalante, Oscar Pérez-Méndez, Adriana Mercado & Rocio Bautista-Pérez. (2022) Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats. International Journal of Molecular Sciences 23:5, pages 2883.
Crossref
Crossref
Donald J. AbrahamAna R. Jesus, Bryce A. Harrison & Timothy M. Dore. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
30
.
Idrisu Sanusi, Alexander Sarnowski, David Russell-Jones & Lui G. Forni. (2020) A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. Journal of Critical Care 57, pages 19-22.
Crossref
Crossref
Ken Kanazawa, Hiroshi Uchino, Fumika Shigiyama, Hiroyuki Igarashi, Kayoko Ikehara, Fukumi Yoshikawa, Shuki Usui, Masahiko Miyagi, Hiroshi Yoshino, Yasuyo Ando, Naoki Kumashiro & Takahisa Hirose. (2019) Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study. Journal of Diabetes Investigation 10:4, pages 1022-1031.
Crossref
Crossref
Joanna Parkinson, Weifeng Tang, Magnus Åstrand, Johanna Melin, Ella Ekholm, Bengt Hamrén & David W. Boulton. (2019) Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism 21:6, pages 1381-1387.
Crossref
Crossref
A Lakshmana Rao, T. Prasanthi & E. L Anusha. (2019) RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND EMPAGLIFLOZIN. INDIAN DRUGS 56:05, pages 68-71.
Crossref
Crossref
Ewa Otto-Buczkowska & Natalia Jainta. (2017) Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?. International Journal of Endocrinology and Metabolism 16:1.
Crossref
Crossref
Nabila Ahmed-Sarwar, Angela K. Nagel, Samantha Leistman & Kevin Heacock. (2017) SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?. Annals of Pharmacotherapy 51:9, pages 791-796.
Crossref
Crossref
Leyna Leite Santos, Fernando José Camello de Lima, Célio Fernando de Sousa-Rodrigues & Fabiano Timbó Barbosa. (2017) Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Revista da Associação Médica Brasileira 63:7, pages 636-641.
Crossref
Crossref
Ralph A. DeFronzo, Luke Norton & Muhammad Abdul-Ghani. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology 13:1, pages 11-26.
Crossref
Crossref
Vasileios Andrianesis, Spyridoula Glykofridi & John Doupis. (2016) The renal effects of SGLT2 inhibitors and a mini-review of the literature. Therapeutic Advances in Endocrinology and Metabolism 7:5-6, pages 212-228.
Crossref
Crossref
Jamila A. Benmoussa, Matthew Clarke, Amulya Penmetsa, Le Yu Khine, Lina Leykina, Keith Diaz & Philip Otterbeck. (2016) Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors. Journal of Clinical and Translational Endocrinology: Case Reports 2, pages 17-19.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2016) Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 24:9, pages 1937-1980.
Crossref
Crossref
Morgan Comee & Anne Peters. (2016) The changing therapeutic armamentarium for patients with type 1 diabetes. Current Opinion in Endocrinology, Diabetes & Obesity 23:2, pages 106-110.
Crossref
Crossref
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux & Po Sing Leung. (2016) The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLOS ONE 11:1, pages e0147391.
Crossref
Crossref
Sudesna Chatterjee & Melanie J Davies. (2015) Current management of diabetes mellitus and future directions in care. Postgraduate Medical Journal 91:1081, pages 612-621.
Crossref
Crossref
Hector E. Tamez, Alejandra L. Tamez, Lucas A. Garza, Mayra I. Hernandez & Ana C. Polanco. (2015) Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Crossref
Rebecca Schechter & Sirimon Reutrakul. (2015) Management of Severe Insulin Resistance in Patients with Type 1 Diabetes. Current Diabetes Reports 15:10.
Crossref
Crossref
Anne L. Peters, Elizabeth O. Buschur, John B. Buse, Pejman Cohan, Jamie C. Diner & Irl B. Hirsch. (2015) Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care 38:9, pages 1687-1693.
Crossref
Crossref
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones & Roselle Herring. (2015) SGLT inhibition and euglycaemic diabetic ketoacidosis. The Lancet Diabetes & Endocrinology 3:7, pages 503-504.
Crossref
Crossref
Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref
Crossref
P. Darmon. (2015) Inhibiteurs de SGLT2 dans le diabète de type 1 : vraie perspective ou fausse bonne idée ?. Médecine des Maladies Métaboliques 9:1, pages S59-S63.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
B Haas, N Eckstein, V Pfeifer, P Mayer & M D S Hass. (2014) Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes 4:11, pages e143-e143.
Crossref
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Crossref